MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
MannKind (Nasdaq: MNKD) has scheduled its third quarter 2024 financial results release for Thursday, November 7, 2024, after market close. The company will host a webcast at 4:30 p.m. Eastern Time to discuss quarterly results and provide a business update. CEO Michael Castagna and CFO Chris Prentiss will lead the conference call. The webcast will be available on MannKind's investor relations website, with a replay accessible for approximately 90 days.
MannKind (Nasdaq: MNKD) ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 per giovedì 7 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà un webcast alle 16:30 ora orientale per discutere i risultati trimestrali e fornire un aggiornamento sull'azienda. Il CEO Michael Castagna e il CFO Chris Prentiss guideranno la conferenza telefonica. Il webcast sarà disponibile sul sito web delle relazioni con gli investitori di MannKind, con una registrazione accessibile per circa 90 giorni.
MannKind (Nasdaq: MNKD) ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 para el jueves 7 de noviembre de 2024, después del cierre del mercado. La compañía realizará un webcast a las 4:30 p.m. hora del Este para discutir los resultados trimestrales y proporcionar una actualización del negocio. El CEO Michael Castagna y el CFO Chris Prentiss liderarán la llamada de conferencia. El webcast estará disponible en el sitio web de relaciones con inversores de MannKind, con una repetición accesible durante aproximadamente 90 días.
MannKind (Nasdaq: MNKD)는 2024년 11월 7일 목요일, 시장 종료 후 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 회사는 동부 표준시 기준 오후 4시 30분에 웹캐스트를 개최하여 분기 실적을 논의하고 사업 업데이트를 제공할 것입니다. CEO 마이클 카스타냐와 CFO 크리스 프렌티스가 컨퍼런스 콜을 이끌 것입니다. 웹캐스트는 MannKind 투자자 관계 웹사이트에서 이용 가능하며, 약 90일 동안 다시 볼 수 있습니다.
MannKind (Nasdaq: MNKD) a programmé la publication de ses résultats financiers du troisième trimestre 2024 pour le jeudi 7 novembre 2024, après la fermeture des marchés. L'entreprise animera un webcast à 16h30, heure de l'Est, pour discuter des résultats trimestriels et fournir une mise à jour sur les activités. Le PDG Michael Castagna et le CFO Chris Prentiss animeront la conférence téléphonique. Le webcast sera disponible sur le site des relations avec les investisseurs de MannKind, avec un enregistrement accessible pendant environ 90 jours.
MannKind (Nasdaq: MNKD) hat die Veröffentlichung seiner finanziellen Ergebnisse für das dritte Quartal 2024 für Donnerstag, den 7. November 2024, nach Börsenschluss angesetzt. Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, um die Quartalsergebnisse zu besprechen und ein Unternehmensupdate zu geben. CEO Michael Castagna und CFO Chris Prentiss werden die Telefonkonferenz leiten. Der Webcast wird auf der Investor-Relations-Website von MannKind verfügbar sein, mit einer Wiederholung, die etwa 90 Tage lang abrufbar ist.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024.
MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
FAQ
When will MannKind (MNKD) release Q3 2024 earnings?
What time is MannKind's (MNKD) Q3 2024 earnings call?
How can I access MannKind's (MNKD) Q3 2024 earnings call?
How long will MannKind's (MNKD) Q3 2024 earnings call replay be available?
